Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celcuity Inc. on June 2, 2026. The filing discloses detailed efficacy and safety results from the PIK3CA mutant-type (MT) cohort of the Phase 3 VIKTORIA-1 clinical trial for gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor. The trial targets adults with hormone receptor positive (HR+), HER2-negative, PIK3CA MT, locally advanced or metastatic breast cancer following progression on prior therapies.
Key Clinical Metrics and Financial Status
The filing focuses on clinical trial outcomes rather than financial performance metrics such as revenue, profit, or cash flow. No financial data is provided in this document.
- Gedatolisib-Triplet vs. Alpelisib + Fulvestrant: Median Progression-Free Survival (PFS) was 11.1 months versus 5.6 months (Hazard Ratio 0.50). Objective Response Rate (ORR) was 48.9% versus 26.0%. Median Duration of Response (DOR) was 15.7 months versus 7.5 months.
- Gedatolisib-Doublet vs. Alpelisib + Fulvestrant: Median PFS was 11.3 months versus 5.6 months (Hazard Ratio 0.51). ORR was 35.7%. Median DOR was 24.2 months.
- Safety Profile: The most common Grade 3+ treatment-related adverse events for the triplet included neutropenia (58.8%), stomatitis (16.3%), and rash (6.5%). Discontinuation rates due to adverse events were 2.6% for the triplet and 3.8% for the doublet, compared to 7.1% for the control arm.
Material Changes and Milestones
The VIKTORIA-1 results represent a significant milestone as the first Phase 3 trial to demonstrate the superiority of one PI3K/AKT/mTOR (PAM) inhibitor over another. The gedatolisib-triplet achieved the highest reported median PFS (11.1 months) and ORR (48.9%) in any Phase 3 trial for second-line HR+/HER2- advanced breast cancer regimens including endocrine therapy.
Guidance, Outlook, and Risks
Regulatory Outlook: Celcuity intends to submit these data to the U.S. FDA as a supplemental New Drug Application (sNDA). The company anticipates a potential FDA approval and commercial launch of gedatolisib in the third quarter of 2026. Additionally, the FDA has granted Priority Review for the NDA regarding the PIK3CA wild-type (WT) indication, with a PDUFA goal date of July 17, 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include the possibility that clinical data may change upon comprehensive review, unforeseen delays in FDA review, failure to obtain regulatory approval, market acceptance issues, and the company's ability to access capital on favorable terms. Overall survival data remains immature.
Investor Verification Checklist
- Verify the specific PDUFA goal date of July 17, 2026, for the PIK3CA wild-type NDA.
- Confirm the timeline for the submission of the sNDA for the PIK3CA mutant-type indication.
- Review the full safety data regarding Grade 3+ neutropenia (58.8%) in the triplet arm to assess commercial viability and management protocols.
- Monitor upcoming filings for updates on the maturity of Overall Survival (OS) data.
- Check the company's cash position in the most recent 10-Q to assess runway for commercialization in Q3 2026.